Zynex Inc. (ZYXI): Price and Financial Metrics
ZYXI Stock Summary
- Price to trailing twelve month operating cash flow for ZYXI is currently 653.11, higher than 99.09% of US stocks with positive operating cash flow.
- Of note is the ratio of Zynex Inc's sales and general administrative expense to its total operating expenses; 87.4% of US stocks have a lower such ratio.
- Revenue growth over the past 12 months for Zynex Inc comes in at 76.2%, a number that bests 93.41% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to Zynex Inc are GDOT, FSS, INOD, SCHN, and SMED.
- Visit ZYXI's SEC page to see the company's official filings. To visit the company's web site, go to www.zynex.com.
ZYXI Stock Price Chart Interactive Chart >
ZYXI Price/Volume Stats
|Current price||$15.22||52-week high||$29.73|
|Prev. close||$15.33||52-week low||$12.13|
|Day high||$15.49||Avg. volume||605,676|
|50-day MA||$16.41||Dividend yield||N/A|
|200-day MA||$16.48||Market Cap||530.49M|
Zynex Inc. (ZYXI) Company Bio
Zynex Inc., through its subsidiary, markets electro therapy products which help improve life of patients who have functional disabilities. The Company's products include muscle stimulation, inferential, and TENS devices. Zynex products are intended for home use for stroke rehabilitation, spinal cord injury rehabilitation, incontinence, and other applications.
ZYXI Latest News Stream
|Loading, please wait...|
ZYXI Latest Social Stream
View Full ZYXI Social Stream
Latest ZYXI News From Around the Web
Below are the latest news stories about Zynex Inc that investors may wish to consider to help them evaluate ZYXI as an investment opportunity.
Zynex ([[ZYXI]] -3.5%) announces Q1 order growth of 140% Y/Y, and confirms its previous revenue estimate 1Q21 of between $23M and $24.5M vs. consensus of $23.8M and Adj. EBITDA loss estimate of between $0.5M and $1.5M.FY21 revenue estimate is between $135M and $150M vs. consensus of $138.03M; and Adj. EBITDA...
Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced that it is moving to a new corporate headquarters to accommodate its' continued growth. The new headquarters is located at 9655 Maroon Circle, Englewood CO 80112.
With its stock down 9.0% over the past month, it is easy to disregard Zynex (NASDAQ:ZYXI). But if you pay close...
Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today announced the Denver Business Journal has recognized Zynex as the sixth largest Biotechnology/Bioscience public company in Colorado based on number of companywide employees as of November 1, 2020.
Shares of Zynex closed 10.1% higher on Monday after the medical device manufacturer announced its plans to repurchase $10 million worth of shares. Zynex (ZYXI) said that the repurchase program will commence immediately and is set to expire on Sep. 8, or before the buyback limit of $10 million is reached. The company’s CEO Thomas Sandgaard said, “this buyback program authorization reflects the board's confidence in both our short-term prospects and our long term growth strategy.” He added that, “the buyback program represents an attractive opportunity to deploy capital in a way that will benefit stockholders.” Last month, Zynex reported lower-than-expected 4Q results. The company reported 4Q earnings of $0.
ZYXI Price Returns
Continue Researching ZYXIHere are a few links from around the web to help you further your research on Zynex Inc's stock as an investment opportunity:
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!